Equities researchers at Credit Suisse hoisted their price target on shares of Seattle Genetics (NASDAQ:SGEN) from $46.00 to $51.00 in a research report issued on Thursday, Stock Ratings News reports. Credit Suisse’s price objective points to a potential upside of 1.76% from the stock’s previous close. Seattle Genetics, Inc.(NASDAQ:SGEN) stock opened at $50.56 in last trading session, and closed at $50.12, trading in the range of $49.08 – $51.51. The stock showed a positive weekly performance of 14.09%.
Halozyme Therapeutics (NASDAQ:HALO) had its price objective hosited by Jefferies Group from $4.00 to $4.50 in a report released on Monday, Analyst Ratings.Net reports. Halozyme Therapeutics, Inc.(NASDAQ:HALO) shares closed at $15.12 on last trade day, by gaining -0.13%. Stock 52 week range is $5.03 – $18.18. Company’s market capitalization is $1.84 billion.
Wedbush lifted their price objective on shares of XOMA Corp. (NASDAQ:XOMA) to $13.00 in a research note issued on Wednesday, StockRatingsNetwork reports. Wedbush’s target price suggests a potential upside of 70.38% from the company’s current price. XOMA Corp(NASDAQ:XOMA) stock decreased -2.00% and finished the last session at $7.34. The EPS of the stock remained -0.80. Company’s market capitalization is $760.62 billion.
Questcor Pharmaceuticals (NASDAQ:QCOR) declared a quarterly dividend on Friday, February 14th, American Banking & Market News reports. Investors of record on Friday, April 18th will be given a dividend of 0.30 per share on Friday, April 25th. This represents a $1.20 dividend on an annualized basis and a yield of 1.73%. Questcor Pharmaceuticals Inc (NASDAQ:QCOR) stock opened at $70.00 in last trading session and closed at $69.28. The 52 week range of the stock is $26.80 – $74.76 and the day range was $68.50 – $70.05.
Leave a Reply